The gluten-Free diet and its current application in coeliac disease and dermatitis Herpetiformis

United European Gastroenterology Journal

Volumn 3, Issue 2, 2015, Pages 121-135

  Ciacci, Carolina ^a   Ciclitira, Paul ^b,c   Hadjivassiliou, Marios ^d   Kaukinen, Katri ^e   Ludvigsson, Jonas F ^f   McGough, Norma ^g   Sanders, David S ^d   Woodward, Jeremy ^h   Leonard, Jonathan N ⁱ   Swift, Gillian L ^j  

^a UNIVERSITY OF SALERNO   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g Policy Research and Campaigns   (United Kingdom)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ ST MARY S HOSPITAL   (United Kingdom)

^j LLANDOUGH HOSPITAL   (United Kingdom)

more..

Author keywords

Coeliac disease; Dermatitis herpetiformis; Gluten free; Gluten free diet; Parts per million

Indexed keywords

GLIADIN; GLUTEN; STARCH;

ATAXIA; CELIAC DISEASE; DERMATITIS HERPETIFORMIS; DIETARY INTAKE; DIETITIAN; FOLLOW UP; GLUTEN FREE DIET; HISTOPATHOLOGY; HUMAN; INTESTINE BIOPSY; NUTRITIONAL STATUS; NUTRITIONAL VALUE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SOCIAL INTERACTION;

EID: 85006186489     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614559263     Document Type: Review

References (155)

1. Dube C, et al. The prevalence of celiac disease in averagerisk and at-risk Western European populations: a systematic review. Gastroenterology 2005; 128(4 Suppl 1): S57–S67.
2. Ludvigsson JF, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62: 43–52.
3. Di Sabatino A and Corazza GR. Coeliac disease. Lancet 2009; 373: 1480–1493.
4. Bolotin D and Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol 2011; 64: 1017–1024; quiz 1025–1026.
5. Ludvigsson JF, et al. Diagnosis and management of adult coeliac disease: Guidelines from the British Society of Gastroenterology. Gut 2014; 63: 1210–1228.
6. Dicke WK. [Treatment of celiac disease]. Ned Tijdschr Geneeskd 1951; 95: 124–130.
7. Van De Kamer JH, Weijers HA and Dicke WK. Coeliac disease. IV. An investigation into the injurious constituents of wheat in connection with their action on patients with coeliac disease. Acta Paediatr 1953; 42: 223–231.
8. Baker G and Read AE. Oats and barley toxicity in coeliac patients. Postgrad Med J 1976; 52: 264–268.
9. Ciacci C, et al. Celiac disease:in vitro and in vivo safety and palatability of wheat-free sorghum food products. Clin Nutr 2007; 26: 799–805.
10. Ukkola A, et al. Patients’ experiences and perceptions of living with coeliac disease–implications for optimizing care. J Gastrointestin Liver Dis 2012; 21: 17–22.
11. McNally SL, et al. Can consumers trust web-based information about celiac disease? Accuracy, comprehensiveness, transparency, and readability of information on the internet. Interact J Med Res 2012; 1: e1.
12. Jackson T, Glasgow JF and Thom R. Parents’ understanding of coeliac disease and diet. Arch Dis Child 1985; 60: 672–674.
13. Tomlin J, Slater H, Muganthan T, et al. Parental knowledge of coeliac disease. Inform Health Soc Care 2014; Epub ahead of print 30 April 2014.
14. Ciacci C, et al. Depressive symptoms in adult coeliac disease. Scand J Gastroenterol 1998; 33: 247–250.
15. Ciacci C, et al. Long-term follow-up of celiac adults on gluten-free diet: Prevalence and correlates of intestinal damage. Digestion 2002; 66: 178–185.
16. Rajani S, et al. Patient and parent satisfaction with a dietitian- and nurse- led celiac disease clinic for children at the Stollery Children’s Hospital, Edmonton, Alberta. Can J Gastroenterol 2013; 27: 463–466.
17. Mahadev S, et al. Is dietitian use associated with celiac disease outcomes? Nutrients 2013; 5: 1585–1594.
18. Ford S, Howard R and Oyebode J. Psychosocial aspects of coeliac disease: A cross-sectional survey of a UK population. Br J Health Psychol 2012; 17: 743–757.
19. Lee AR, et al. Living with coeliac disease: Survey results from the USA. J Hum Nutr Diet 2012; 25: 233–238.
20. Bystrom IM, et al. Health-related quality of life in children and adolescents with celiac disease: From the perspectives of children and parents. Gastroenterol Res Pract 2012; 2012: 986-475.
21. Ciclitira J, et al. Clinical testing of gliadin fractions in coeliac patients. Clin Sci (Lond) 1984; 66: 357–364.
22. Ciclitira J, et al. A radioimmunoassay for wheat gliadin to assess the suitability of gluten free foods for patients with coeliac disease. Clin Exp Immunol 1985; 59: 703–708.
23. Catassi C, et al. Dose dependent effects of protracted ingestion of small amounts of gliadin in coeliac disease children: A clinical and jejunal morphometric study. Gut 1993; 34: 1515–1519.
24. Montgomery AM, et al. Low gluten diet in the treatment of adult coeliac disease: Effect on jejunal morphology and serum anti-gluten antibodies. Gut 1988; 29: 1564–1568
25. Catassi C, et al. A prospective, double-blind, placebocontrolled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 160–166.
26. Leffler D, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62: 996–1004.
27. Akobeng AK and Thomas AG. Systematic review: Tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther 2008; 27: 1044–1052.
28. Hernando A, et al. Measurement of wheat gluten and barley hordeins in contaminated oats from Europe, the United States and Canada by Sandwich R5 ELISA. Eur J Gastroenterol Hepatol 2008; 20: 545–554.
29. Arentz-Hansen H, et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med 2004; 1: e1.
30. Guttormsen V, et al. No induction of anti-avenin IgA by oats in adult, diet-treated coeliac disease. Scand J Gastroenterol 2008; 43: 161–165.
31. NIH Consensus Development Conference on Celiac Disease. NIH Consens State Sci Statements 2004; 21: 1–23.
32. Silano M, et al. In vitro tests indicate that certain varieties of oats may be harmful to patients with coeliac disease. J Gastroenterol Hepatol 2007; 22: 528–531.
33. Pulido OM, et al. Introduction of oats in the diet of individuals with celiac disease: A systematic review. Adv Food Nutr Res 2009; 57: 235–285.
34. Cooper SE, et al. Immunological indicators of coeliac disease activity are not altered by long-term oats challenge. Clin Exp Immunol 2013; 171: 313–318.
35. Haboubi NY, Taylor S and Jones S. Coeliac disease and oats: A systematic review. Postgrad Med J 2006; 82: 672–678.
36. Fric P, Gabrovska D and Nevoral J. Celiac disease, gluten-free diet, and oats. Nutr Rev 2011; 69: 107–115.
37. Tjellstrom B, et al. The effects of oats on the function of gut microflora in children with coeliac disease. Aliment Pharmacol Ther 2014; 39: 1156–1160.
38. Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med 2004; 351: 2021–2022.
39. Garsed K and Scott BB. Can oats be taken in a glutenfree diet? A systematic review. Scand J Gastroenterol 2007; 42: 171–178.
40. Rashid M, et al. Consumption of pure oats by individuals with celiac disease: A position statement by the Canadian Celiac Association. Can J Gastroenterol 2007; 21: 649–651.
41. Codex Alimentarius Standard. Codex standard for foods for special dietary use for persons intolerant to gluten. Available at: www.codexalimentarius.net/input/download/standards/291/cxs_118e.pdf 2008.
42. European Commission, COMMISSION REGULATION No 41/2009 of 20 January 2009 concerning the composition and labelling of foodstuffs suitable for people intolerant to gluten, 2009. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri¼OJ:L:2009:016:0003:0005:EN:PDF.
43. Storsrud S, Malmheden Yman I and Lenner RA. Gluten contamination in oat products and products naturally free from gluten. Eur Food Res Technol 2003; 217: 481–485.
44. Collin P, et al. The safe threshold for gluten contamination in gluten-free products Can trace amounts be accepted in the treatment of coeliac disease?. Aliment Pharmacol Ther 2004; 19: 1277–1283.
45. Thompson T, Lee AR and Grace T. Gluten contamination of grains, seeds, and flours in the United States: A pilot study. J Am Diet Assoc 2010; 110: 937–940.
46. Hischenhuber C, et al. Review article:safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006; 23: 559–575.
47. Gibert A, et al. Might gluten traces in wheat substitutes pose a risk in patients with celiac disease? A populationbased probabilistic approach to risk estimation. Am J Clin Nutr 2013; 97: 109–116.
48. Koning F, Mol M and Mearin ML. The million-dollar question: Is ‘‘gluten-free’’ food safe for patients with celiac disease? Am J Clin Nutr 2013; 97: 3–4.
49. Ciclitira J, et al. Evaluation of a gliadin-containing gluten-free product in coeliac patients. Hum Nutr Clin Nutr 1985; 39C: 303–308.
50. Collin P, et al. Coeliac disease – associated disorders and survival. Gut 1994; 35: 1215–1218.
51. Kaukinen K, et al. Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. Scand J Gastroenterol 1999; 34: 164–169.
52. Collin P, Maki M and Kaukinen K. Complete small intestine mucosal recovery is obtainable in the treatment of celiac disease. Gastrointest Endosc 2004; 59: 158–159; author reply 159–160.
53. Peräaho M, et al. Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease.Prospective and randomized study. Aliment Pharmacol Ther 2003; 17: 587–594.
54. Food labeling: Gluten-free labeling of foods. Final rule. Fed Regist 2013; 78: 47154–47179.
55. Valdes I, et al. Innovative approach to low-level gluten determination in foods using a novel sandwich enzymelinked immunosorbent assay protocol. Eur J Gastoenterol Hepatol 2003; 15: 465–474.
56. Kanerva M, et al. Analysis of barley contamination in oats using R5 and omega-gliadin antibodies. J Cereal Sci 2006; 44: 347–352.
57. Thompson T and Méndez E. Commercial assays to assess gluten content of gluten-free foods: Why they are not created equal. J Am Diet Assoc 2008; 108: 1682–1687.
58. Kaukinen K, et al. Clinical trial: Gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients – a randomized, double-blind, placebo-controlled study to evaluate safety. Aliment Pharmacol Ther 2008; 28: 1240–1248.
59. Molberg Ø, et al. Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 2003; 125: 337–344.
60. Picariello G, et al. Shotgun proteome analysis of beer and the immunogenic potential of beer polypeptides. J Proteomics 2012; 75: 5872–5882.
61. Dostálek P, et al. Immunochemical determination of gluten in malts and beers. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2006; 23: 1074–1078.
62. Mujico JR, et al. Validation of a new enzyme-linked immunosorbent assay to detect the triggering proteins and peptides for celiac disease: Interlaboratory study. J AOAC Int 2012; 95: 206–215.
63. Nassef HM, et al. Electrochemical immunosensor for detection of celiac disease toxic gliadin in foodstuff. Anal Chem 2008; 80: 9265–9271.
64. Hernando A, et al. Confirmation of the cereal type in oat products highly contaminated with gluten. J Am Diet Assoc 2006; 106: 665–666.
65. Koerner TB, et al. Gluten contamination in the Canadian commercial oat supply. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011; 28: 705–710.
66. Wahab J, Meijer JW and Mulder CJ. Histologic followup of people with celiac disease on a gluten-free diet: Slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459–463.
67. Lee SK, et al. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57: 187–191.
68. Lanzini A, et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009; 29: 1299–1308.
69. Bardella MT, et al. Coeliac disease: A histological followup study. Histopathology 2007; 50: 465–471.
70. Hollon JR, et al. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. BMC Gastroenterol 2013; 13: 40.
71. Lebwohl B, et al. Persistent mucosal damage and risk of fracture in celiac disease. J Clin Endocrinol Metab 2014; 99: 609–616.
72. Lebwohl B, et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: A populationbased cohort study. Ann Intern Med 2013; 159: 169–175.
73. Kaukinen K, et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007; 25: 1237–1245.
74. Rubio-Tapia A, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a glutenfree diet. Am J Gastroenterol 2010; 105: 1412–1420.
75. Singh J and Whelan K. Limited availability and higher cost of gluten-free foods. J Hum Nutr Diet 2011; 24: 479–486.
76. Stevens L and Rashid M. Gluten-free and regular foods: A cost comparison. Can J Diet Pract Res 2008; 69: 147–150.
77. Lee AR, et al. Economic burden of a gluten-free diet. J Hum Nutr Diet 2007; 20: 423–430.
78. Passananti V, et al. Prevalence of eating disorders in adults with celiac disease. Gastroenterol Res Pract 2013; 2013: 491-657.
79. Wild D, et al. Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. Aliment Pharmacol Ther 2010; 32: 573–581.
80. Mariani P, et al. The gluten-free diet: A nutritional risk factor for adolescents with celiac disease. J Pediatr Gstroenterol Nutr 1998; 27: 519–523.
81. Pietzak M. Gluten-free food labeling in the United States. J Pediatr Gastroenterol Nutr 2005; 41: 567–568.
82. Karajeh MA, et al. Chefs’ knowledge of coeliac disease (compared to the public): A questionnaire survey from the United Kingdom. Clin Nutr 2005; 24: 206–210.
83. Zarkadas M, et al. The impact of a gluten-free diet on adults with coeliac disease: Results of a national survey. J Hum Nutr Diet 2006; 19: 41–49.
84. Rashid M, et al. Celiac disease: Evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics 2005; 116: e754–e759.
85. Whitaker JKH, et al. Patient perceptions of the burden of coeliac disease and treatment in the UK. Aliment Pharmacol Ther 2009; 29: 1131–1136.
86. Holden SE. Gluten-free foods and the cost of prescriptions. J Hum Nutr Diet 2012; 25: 405.
87. Zuccotti G, et al. Intakes of nutrients in Italian children with celiac disease and the role of commercially available gluten-free products. J Hum Nutr Diet 2013; 26: 436–444.
88. Wierdsma NJ, et al. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Nutrients 2013; 5: 3975–3992.
89. Martin J, et al. Inadequate nutrient intake in patients with celiac disease: Results from a German dietary survey. Digestion 2013; 87: 240–246.
90. Shepherd SJ and Gibson R. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and longterm patients with coeliac disease. J Hum Nutr Diet 2013; 26: 349–358.
91. Ciacci C, et al. Low plasma cholesterol: A correlate of nondiagnosed celiac disease in adults with hypochromic anemia. Am J Gastroenterol 1999; 94: 1888–1891.
92. Zanini B, et al. Impact of gluten-free diet on cardiovascular risk factors. A retrospective analysis in a large cohort of coeliac patients. Dig Liver Dis 2013; 45: 810–815.
93. De Marchi S, et al. Young adults with coeliac disease may be at increased risk of early atherosclerosis. Aliment Pharmacol Ther 2013; 38: 162–169.
94. Emilsson L, et al. The characterisation and risk factors of ischaemic heart disease in patients with coeliac disease. Aliment Pharmacol Ther 2013; 37: 905–914.
95. Chung DJ, et al. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes. J Bone Miner Metab 2013; 31: 161–168.
96. Ciacci C, et al. Effects of dietary treatment on bone mineral density in adults with celiac disease: Factors predicting response. Am J Gastroenterol 1997; 92: 992–996.
97. Fouda MA, et al. Evaluation and management of skeletal health in celiac disease: Positi on statement. Can J Gastroenterol 2012; 26: 819–829.
98. Bardella MT, et al. Need for follow up in coeliac disease. Arch Dis Child 1994; 70: 211–213.
99. Lebwohl B, et al. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013; 37: 332–339.
100. Ciacci C, et al. The use of serum tTG-ab assay in patients on gluten-free diet as a measure of dietetic compliance. Gastroenterology 2002; 122: 588.
101. http://pda.tucows.com/pocket/preview/152569.html.
102. Hallert C and Sedvall G. Improvement in central monoamine metabolism in adult coeliac patients starting a gluten-free diet. Psychol Med 1983; 13: 267–271.
103. Kurppa K, et al. Factors associated with dietary adherence in celiac disease: A nationwide study. Digestion 2012; 86: 309–314.
104. Gallagher E, Gormley TR and Arendt EK. Recent advances in the formulation of gluten-free cereal-based products. Trends Food Sci Technol 2004; 15: 143–152.
105. Thompson T, et al. Gluten-free diet survey: Are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet 2005; 18: 163–169.
106. Walters JR. Analysis of the absolute risks in coeliac disease indicates the importance of the prevention of osteoporosis. Gut 2007; 56: 310, author reply 310–311.
107. Green HR, et al. Characteristics of adult celiac disease in the USA: Results of a national survey. Am J Gastroenterol 2001; 96: 126–131.
108. Samasca G, et al. Gluten-free diet and quality of life in celiac disease. Gastroenterol Hepatol Bed Bench 2014; 7: 139–143.
109. Abdulkarim AS, et al. Etiology of nonresponsive celiac disease: Results of a systematic aproach. Am J Gastroenterol 2002; 97: 2016–2021.
110. Lundin KE, et al. Oats induced villous atrophy in coeliac disease. Gut 2003; 52: 1649–1652.
111. Ortiz-Sanchez J, Cabrera-Chavez F and de la Barca AM. Maize prolamins could induce a gluten-like cellular immune response in some celiac disease patients. Nutrients 2013; 5: 4174–4183.
112. Lahdeaho ML, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014; 146: 1649–1658.
113. Wang C, et al. 929b larazotide acetate, a first in-class, novel tight junction regulator, meets primary endpoint and significantly reduces signs and symptoms of celiac disease in patients on a gluten-free diet: Results of a multicenter, randomized, placebo controlled trial. Gastroenterology 146: S159.
114. Malamut G, et al. Refractory celiac disease: From bench to bedside. Semin Immunopathol 2012; 34: 601–613.
115. Tursi A, Brandimarte G and Giorgetti GM. Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003; 37: 387–391.
116. Vahedi K, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003; 98: 1079–1087.
117. Millward C, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008: CD003498.
118. Jackson J, et al. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res 2012; 140: 262–263.
119. Bolotin D and Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol 2011; 64: 1027–1033; quiz 1033–1034.
120. Fry L, et al. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet 1973; 1: 288–291.
121. Reunala T, et al. Gluten-free diet in dermatitis herpetiformis. I. Clinical response of skin lesions in 81 patients. Br J Dermatol 1977; 97: 473–480.
122. Gawkrodger DJ, et al. Dermatitis herpetiformis: Diagnosis, diet and demography. Gut 1984; 25: 151–157.
123. Collin P and Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: A guide for dermatologists. Am J Clin Dermatol 2003; 4: 13–20.
124. Fry L, et al. Long-term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal. Br J Dermatol 1982; 107: 631–640.
125. Garioch JJ, et al. 25 years’ experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131: 541–545.
126. Fry L, et al. Gluten-free diet and reintroduction of gluten in dermatitis herpetiformis. Arch Dermatol 1969; 100: 129–135.
127. Leonard J, et al. Gluten challenge in dermatitis herpetiformis. N Engl J Med 1983; 308: 816–819.
128. Hardman CM, et al. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1997; 337: 1884–1887.
129. Leonard JN, et al. Increased incidence of malignancy in dermatitis herpetiformis. Br Med J (Clin Res Ed) 1983; 286: 16–18.
130. Lewis HM, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996; 135: 363–367.
131. Hadjivassiliou M, et al. Gluten sensitivity: From gut to brain. Lancet Neurol 2010; 9: 318–330.
132. Gobbi G, et al. Coeliac disease, epilepsy, and cerebral calcifications. The Italian Working Group on Coeliac Disease and Epilepsy. Lancet 1992; 340: 439–443.
133. Currie S, Hoggard N, Sandres DS, et al. Coeliac disease and neurological dysfunction: A case control study. Lancet 2014; 383: S39.
134. Hadjivassiliou M, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. Neurology 2013; 80: 1740–1745.
135. Hadjivassiliou M, et al. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry 2003; 74: 1221–1224.
136. Hadjivassiliou M, et al. Dietary treatment of gluten neuropathy. Muscle Nerve 2006; 34: 762–766.
137. Hadjivassiliou M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology 2001; 56: 385–388.
138. Jones E, Pallis C and Peters TJ. Morphological and biochemical findings in jejunal biopsies from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1979; 42: 402–406.
139. Dahl R. Wheat sensitive – but not coeliac. Lancet 1979; 1: 43–44.
140. Cooper BT, et al. Gluten-sensitive diarrhea without evidence of celiac disease. Gastroenterology 1980; 79: 801–806.
141. Pastorello EA, et al. Wheat IgE-mediated food allergy in European patients: Alpha-amylase inhibitors, lipid transfer proteins and low-molecular-weight glutenins. Allergenic molecules recognized by double-blind, placebo- controlled food challenge. Int Arch Allergy Immunol 2007; 144: 10–22.
142. Carroccio A, et al. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: Exploring a new clinical entity. Am J Gastroenterol 2012; 107: 1898–1906; quiz 1907.
143. Volta U, et al. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med 2014; 12: 85.
144. Matsuo H, et al. Identification of the IgE-binding epitope in omega-5 gliadin, a major allergen in wheatdependent exercise-induced anaphylaxis. J Biol Chem 2004; 279: 12135–12140.
145. Shepherd SJ, et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008; 6: 765–771.
146. Gibson R and Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol 2012; 107: 657–666; quiz 667.
147. Biesiekierski JR, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106: 508–514; quiz 515.
148. Biesiekierski JR, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, shortchain carbohydrates. Gastroenterology 2013; 145: 320–328; e1–3.
149. Sapone A, et al. Divergence of gut permeability and mucosal immune gene expression in two glutenassociated conditions: Celiac disease and gluten sensitivity. BMC Med 2011; 9: 23.
150. Maiuri L, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003; 362: 30–37.
151. Hue S, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367–377.
152. Lammers KM, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008; 135: 194–204; e3.
153. Peron A, et al. Effects of two wheat cultivars on physico-chemical properties of wheat flours and digesta from two broiler chicken lines (Dþ and D-) differing in digestion capacity. Br Poult Sci 2007; 48: 370–380.
154. Biesiekierski JR, et al. Characterization of adults with a self-diagnosis of nonceliac gluten sensitivity. Nutr Clin Pract 2014; 29: 504–509.
155. Hopper AD, Hadjivassiliou M, Hurlstone DP, et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008; 6: 314–320